Fevipiprant, a selective prostaglandin D2 receptor 2 antagonist, inhibits human group 2 innate lymphoid cell aggregation and function

J Allergy Clin Immunol. 2019 Jun;143(6):2329-2333. doi: 10.1016/j.jaci.2019.02.015. Epub 2019 Feb 28.
No abstract available

Publication types

  • Letter
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Cell Aggregation / drug effects
  • Cytokines / genetics
  • Cytokines / metabolism
  • Humans
  • Immunity, Innate / drug effects
  • Indoleacetic Acids / pharmacology*
  • Lymphocytes / drug effects*
  • Lymphocytes / physiology
  • Pyridines / pharmacology*
  • Receptors, Immunologic / antagonists & inhibitors*
  • Receptors, Prostaglandin / antagonists & inhibitors*

Substances

  • Cytokines
  • Indoleacetic Acids
  • Pyridines
  • Receptors, Immunologic
  • Receptors, Prostaglandin
  • fevipiprant
  • prostaglandin D2 receptor